ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 19/3024% above fair value
$1409.38−1.61 (-0.11%)
Close on Nov 3, 2026Market cap $1.33TP/E 45.7Yield 0.44%
Eli Lilly Alimta (pemetrexed) by Year
Alimta (pemetrexed) — Worldwide revenue YoY (%) [legacy] (%)
Eli Lilly Alimta (pemetrexed): -77.0% in FY2023, down 22.0 pts from a year earlier. No newer figure appears in the documents we track.
Latest, FY2023
-77.0%
Period ended Dec 31, 2023
Change on a year earlier
-22.0 pts
-55.0% in FY2022
History
7 years
Since FY2017
Sources
7
Documents cited below
Where the FY2023 figure comes from
“|| Alimta | 72.9 | 144.6 | 217.5 | 927.7 | (77)”
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Alimta (pemetrexed) — Worldwide revenue YoY (%) [legacy] (%) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | -77.0% | -22.0 pts | Form 10-K FY2023 (filed 2024-02-21) ↗ |
| FY2022 | Dec 31, 2022 | -55.0% | -43.0 pts | Form 10-K FY2022 (filed 2023-02-22) ↗ |
| FY2021 | Dec 31, 2021 | -12.0% | -22.0 pts | Form 10-K FY2021 (filed 2022-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 10.0% | +7.0 pts | Form 10-K FY2020 (filed 2021-02-17) ↗ |
| FY2019 | Dec 31, 2019 | 3.0% | +13.0 pts | Form 10-K FY2019 (filed 2020-02-19) ↗ |
| FY2018 | Dec 31, 2018 | -10.0% | -2.0 pts | Form 10-K FY2018 (filed 2019-02-19) ↗ |
| FY2017 | Dec 31, 2017 | -8.0% | – | Form 10-K FY2017 (filed 2018-02-20) ↗ |
Cite this data
StockData. (2026). Eli Lilly Alimta (pemetrexed) (%), annual FY2017–FY2023 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-alimta-yoy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.
See a number that looks wrong?